Cancer, Small cell lung cancer
GNLXGenelux CorporationCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Olvi-Vec (Olvimulogene nanivacirepvec) in Cancer, Small cell lung cancer. The expected timing is based on the latest available company guidance and may change.
Partnered w/ Newsoara. Initiated trial in China in H1 2023. 11/14/23- Ongoing trial. 3/25/25- Announced Ph1b data. 3/28/25- Enrollment ongoing. 8/7/25- Interim results in H2 2025. 11/05/25:- Systemic SCLC Ph1b/2 trial enrollment ongoing; additional interim data from lung cancer programs expected in Q4 2025 and further updates through 2026. 01/05/26:- Interim OLVI-VEC-SCLC-202 Ph1b/2 data show responses; further systemic lung cancer readouts expected throughout 2026. 03/19/26:- OLVI-VEC-SCLC-202 interim data show 33% partial responses, 67% disease control; more dose-finding updates expected 2026. 05/07/26:- January 2026 SCLC OLVI-VEC-SCLC-202 data reiterated; additional dose-finding updates expected throughout 2026. 08/13/26:- OLVI-VEC-SCLC-202 dose-finding updates are expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.